Eunice Wang, MD

Chief of the leukemia service and professor of oncology at the Roswell Park Comprehensive Cancer Center

Articles by Eunice Wang, MD

The Potential of CAR T-Cell Therapy in Adult ALL

July 16th 2021

Eunice Wang, MD, and Bijal Shah, MD, MS, discussed unmet needs for adult patients with relapsed/refractory ALL and reflect on the current treatment landscape.

The Use of Clinical Endpoints in the ZUMA-3 Trial

ByEunice Wang, MD,Bijal D. Shah, MD

July 14th 2021

Bijal Shah, MD, MS, and Eunice Wang, MD, discussed the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy.

Safety and Efficacy of the ZUMA-3 Trial

ByEunice Wang, MD,Bijal D. Shah, MD

July 13th 2021

Bijal Shah, MD, MS, and Eunice Wang, MD, discuss efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and review key safety data.

ZUMA Trial of CAR T-Cell Therapy in R/R ALL

ByEunice Wang, MD,Bijal D. Shah, MD

July 12th 2021

Eunice Wang, MD, and Bijal Shah, MD, MS, discuss the overall study design and patient population of the ZUMA-3 trial of CAR T-cell therapy in adult patients with R/R ALL.

Using MRD to Monitor CAR T Response in ALL

ByEunice Wang, MD,Bijal D. Shah, MD

July 10th 2021

Eunice Wang, MD, and Bijal Shah, MD, MS, discussed the use of MRD status to assess therapeutic response and guide treatment decisions in patients with relapsed/refractory ALL.